001     1018548
005     20231213115653.0
024 7 _ |a 10.1007/s11060-023-04444-x
|2 doi
024 7 _ |a 0167-594X
|2 ISSN
024 7 _ |a 1573-7373
|2 ISSN
024 7 _ |a 10.34734/FZJ-2023-04876
|2 datacite_doi
024 7 _ |a 37728779
|2 pmid
024 7 _ |a WOS:001068390300001
|2 WOS
037 _ _ |a FZJ-2023-04876
082 _ _ |a 610
100 1 _ |a Zeyen, Thomas
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
260 _ _ |a Dordrecht [u.a.]
|c 2023
|b Springer Science + Business Media B.V
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1701182095_23345
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Erratum in Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. J Neurooncol. 2023 Nov 3. doi: 10.1007/s11060-023-04488-z.
520 _ _ |a Purpose: In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and pseudoprogression rates (about 10%) were similar in both arms. Further evaluating this discrepancy, we analyzed patterns of postprogression survival (PPS) and MRI features at first progression according to modified RANO criteria (mRANO).Methods: We classified the patients of the CeTeG/NOA-09 trial according to long vs. short PPS employing a cut-off of 18 months and compared baseline characteristics and survival times. In patients with available MRIs and confirmed progression, the increase in T1-enhancing, FLAIR hyperintense lesion volume and the change in ADC mean value of contrast-enhancing tumor upon progression were determined.Results: Patients with long PPS in the CCNU/TMZ arm had a particularly short PFS (5.6 months). PFS in this subgroup was shorter than in the long PPS subgroup of the TMZ arm (11.1 months, p = 0.01). At mRANO-defined progression, patients of the CCNU/TMZ long PPS subgroup had a significantly higher increase of mean ADC values (p = 0.015) and a tendency to a stronger volumetric increase in T1-enhancement (p = 0.22) as compared to long PPS patients of the TMZ arm.Conclusion: The combination of survival and MRI analyses identified a subgroup of CCNU/TMZ-treated patients with features that sets them apart from other patients in the trial: short first PFS despite long PPS and significant increase in mean ADC values upon mRANO-defined progression. The observed pattern is compatible with the features commonly observed in pseudoprogression suggesting mRANO-undetected pseudoprogressions in the CCNU/TMZ arm of CeTeG/NOA-09.Keywords: Glioblastoma; MGMT promotor methylation; MRI; Progression; Pseudoprogression.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
536 _ _ |a DFG project 491111487 - Open-Access-Publikationskosten / 2022 - 2024 / Forschungszentrum Jülich (OAPKFZJ) (491111487)
|0 G:(GEPRIS)491111487
|c 491111487
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Paech, Daniel
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Weller, Johannes
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Schäfer, Niklas
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Tzaridis, Theophilos
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Duffy, Cathrina
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Nitsch, Louisa
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Schneider, Matthias
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Potthoff, Anna-Laura
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Steinbach, Joachim Peter
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Hau, Peter
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Schlegel, Uwe
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Seidel, Clemens
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Krex, Dietmar
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Grauer, Oliver
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Goldbrunner, Roland
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Zeiner, Pia Susan
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Tabatabai, Ghazaleh
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 18
|u fzj
700 1 _ |a Stummer, Walter
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Hattingen, Elke
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Glas, Martin
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Radbruch, Alexander
|0 P:(DE-HGF)0
|b 22
700 1 _ |a Herrlinger, Ulrich
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Schaub, Christina
|0 0000-0002-5257-4183
|b 24
|e Corresponding author
773 _ _ |a 10.1007/s11060-023-04444-x
|g Vol. 164, no. 3, p. 607 - 616
|0 PERI:(DE-600)2007293-4
|n 3
|p 607 - 616
|t Journal of neuro-oncology
|v 164
|y 2023
|x 0167-594X
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/1018548/files/PDF.pdf
856 4 _ |y OpenAccess
|x icon
|u https://juser.fz-juelich.de/record/1018548/files/PDF.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://juser.fz-juelich.de/record/1018548/files/PDF.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://juser.fz-juelich.de/record/1018548/files/PDF.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://juser.fz-juelich.de/record/1018548/files/PDF.jpg?subformat=icon-640
909 C O |o oai:juser.fz-juelich.de:1018548
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 18
|6 P:(DE-Juel1)143792
910 1 _ |a UK Bonn
|0 I:(DE-HGF)0
|b 24
|6 0000-0002-5257-4183
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-20
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEURO-ONCOL : 2022
|d 2023-08-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-20
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-20
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-20
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-20
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-20
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-20
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-20
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21